OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
The Montana-based compounder commits to supporting prescribers and patients in wake of competitor’s abrupt exit of California market
According to a Feb. 2, 2026 company disclosure, ImprimisRx – the compounding division of Harrow (NASDAQ:HROW) – voluntarily forfeited its California license on February 1 and agreed to pay an administrative fine of approximately $157,000 as part of a settlement agreement reached with the California Board of Pharmacy (CBOP).1 The CBOP previously filed a formal accusation against ImprimisRx in August 2025 outlining multiple causes for discipline.2
This licensing action pertains solely to ImprimisRx and does not affect other 503B outsourcing facilities in good standing with the California Board of Pharmacy, including OSRX.
OSRX remains fully licensed, fully operational, and prepared to support practices without interruption, including those navigating medication supply changes.
Key Facts
- Effective February 1, 2026, ImprimisRx voluntarily exited the California market.
- This licensing action applies solely to ImprimisRx and does not impact other FDA-registered 503B outsourcing facilities in good standing with the California Board of Pharmacy, including OSRX.
- OSRX is an FDA-registered and California-licensed 503B outsourcing facility and is licensed and operational in all 50 states.
Many ophthalmology practices rely on compounded medications for post-operative care, glaucoma management, and myopia control. OSRX continues to provide a portfolio of compounded ophthalmic formulations and supports both direct-to-patient and direct-to-facility dispensing models.
“California clinicians and their patients can rely on OSRX for uninterrupted access to high-quality compounded medications,” said Anthony Sampietro, Founder and CEO of OSRX. “We currently support thousands of ophthalmologists and optometrists nationwide and are prepared to assist any practice navigating medication supply changes.”
Read the full press release here via BusinessWire.
If your practice is experiencing supply disruptions or evaluating compounding partners, our team is here to help.